Study of ASP5834 for advanced solid tumors with KRAS changes
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor cancer that has spread (advanced or metastatic) and has a specific change in the KRAS gene (a mutation like G12V, G12D, G12C, G12R, G12A, or G13D) or extra copies of the KRAS gene (amplification).
- Your cancer must have already been treated with standard therapy, or you must not be able to receive standard treatment due to medical reasons.
- You must have at least one tumor that can be measured on imaging scans, and your overall health status must be good (ECOG score 0 or 1).
- You must be willing to provide tumor tissue samples (an existing one or a new biopsy), and have another biopsy during the study.
- You cannot have untreated or symptomatic brain metastases, active hepatitis B or C, a history of HIV with complications, recent heart problems, or significant electrolyte imbalances.
- If you've had a prior KRAS-targeting treatment, you may still be able to participate in certain parts of the trial (with exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This trial tests an experimental drug (GDC-7035) given with other cancer treatments to see if it is safe and works in people with advanced colorectal or pancreatic cancer that has a specific genetic change called KRAS G12D.
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.